Quantifying the effect of metformin treatment and dose on glycemic control

Diabetes Care

Volumn 35, Issue 2, 2012, Pages 446-454

  Hirst, Jennifer A ^a,b   Farmer, Andrew J ^a,b   Ali, Raghib ^c,d   Roberts, Nia W ^a   Stevens, Richard J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Manchester   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL PAIN; ADD ON THERAPY; ARTICLE; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FLATULENCE; GLYCEMIC CONTROL; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 84859097414     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1465     Document Type: Article

References (21)

1. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends intreatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
2. National Health Service. Prescribing for diabetes in England: 2004/5 to 2009/10 [article online], 2010. Available fromhttp:// www.ic.nhs.uk/webfiles/ publications/Primary %20Care/Prescriptions/prescribingdiabetes/ Prescribing%20for%20Diabetes%20in %20England%2020045%20to%20200910. pdf. Accessed 5 December 2011
3. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52: 17-30
4. National Institute for Health and Clinical Excellence. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update) [article online], 2008. Available from http://www.nice.org.uk/ nicemedia/live/11983/40803/40803.pdf. Accessed 5 December 2011
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
6. Selvin E, Bolen S, Yeh H-C, et al. Cardiovascular outcomes intrials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-2080
7. Nathan DM. Finding new treatments for diabetesdhow many, how fast... how good? N Engl J Med 2007;356:437-440 (Pubitemid 46193068)
8. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010;33:1859-1864
9. Higgins JPT, Deeks JJ, Altman DG, Eds (2011). Chapter 16: Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions [Internet], 2011, Version 5.1.0. The Cochrane Collaboration. Available from http://www.cochrane-handbook.org/. Accessed 5 December 2011
10. Chiasson JL, Naditch L; Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001;24:989-994
11. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-549
12. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987 (Pubitemid 47219404)
13. Wolever TMS, Assiff L, Basu T, et al. Miglitol, analpha-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Nutr Res 2000;20:1447-1456
14. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009;25:569-583
15. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389-396 (Pubitemid 29111220)
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-865
17. British Medical Association. QOF guidance, fourth revision 2011-2012 [article online], 2011. Available from http://www.bma.org.uk/ employmentandcontracts/independent-contractors/quality-outcomes-framework/ qofguidance2011.jsp. Accessed 5 December 2011
18. American Diabetes Association. Standards of medical care in diabetesd2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
19. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010;27:309-317
20. Higgins JPT, Green S, Eds. Cochrane Handbook for Systematic Reviews of Interventions [Internet], 2011. Version 5.1.0. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Accessed 5 December 2011
21. Bailey CJ, Turner RC. Metformin. N Engl JMed 1996;334:574-579 (Pubitemid 126537875)